Transpara®

FDA, CE & Health Canada | Breast | DBT & FFDM | Amplifier Partner

Description of use

Transpara analyzes mammograms to improve reading accuracy. 70% of studies will show low risk (no marks) for confident and fast negative reading. 30% of studies will show markings based on mass or calcification and the characteristics of each will determine an ELEVATED or INTERMEDIATE risk score for the exam. Clear exam risk categorization (Elevated, Intermediate, Low) can enable radiologists to detect cancer more effectively. The Transpara Report is a summary that includes exam risk, an overview of regions of concern across all views, and relevant region finding scores.

Applying the algorithm to screening studies has been used by existing customers to:

  • Confidently eliminate double reading on low-risk studies
  • Save time when reading DBT studies
  • Prioritize high risk studies for reading

The application content is provided by the respective AI vendors.